---
document_datetime: 2025-12-02 06:14:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-bgr.html
document_name: clopidogrel-bgr.html
version: success
processing_time: 0.1272057
conversion_datetime: 2025-12-30 02:01:32.309646
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Clopidogrel BGR (previously Zylagren)

[RSS](/en/individual-human-medicine.xml/66304)

##### Authorised

This medicine is authorised for use in the European Union

clopidogrel Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Clopidogrel BGR](#more-information-on-clopidogrel-bgr-1263)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Clopidogrel BGR. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel BGR.

Expand section

Collapse section

## What is Clopidogrel BGR?

Clopidogrel BGR is a medicine that contains the active substance clopidogrel. It is available astablets (75 mg).

Clopidogrel BGR is a 'generic medicine'. This means that Clopidogrel BGR is similar to a 'reference medicine' already authorised in the European Union (EU) called Plavix.

## What is Clopidogrel BGR used for?

Clopidogrel BGR is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). Clopidogrel BGR can be given to the following groups of patients:

- patients who have recently had a myocardial infarction (heart attack). Clopidogrel BGR can be started between a few days and 35 days after the attack;
- patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Clopidogrel BGR can be started between seven days and six months after the stroke;
- patients with peripheral arterial disease (problems with blood flow in the arteries).

The medicine can only be obtained with a prescription.

## How is Clopidogrel BGR used?

The standard dose of Clopidogrel BGR is one 75 mg tablet once a day.

## How does Clopidogrel BGR work?

The active substance in Clopidogrel BGR, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming 'sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

## How has Clopidogrel BGR been studied?

Because Clopidogrel BGR is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Clopidogrel BGR?

Because Clopidogrel BGR is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

## Why has Clopidogrel BGR been approved?

The CHMP concluded that, in accordance with EU requirements, Clopidogrel BGR has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk. The Committee recommended that Clopidogrel BGR be given marketing authorisation.

## Other information about Clopidogrel BGR

The European Commission granted a marketing authorisation valid throughout the EU for Zylagren on 21 September 2009. The name of the medicine was changed to Clopidogrel BGR on 14 July 2014.

For more information about treatment with Clopidogrel BGR, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Clopidogrel BGR (previously Zylagren) : EPAR - Summary for the public

Reference Number: EMA/658100/2014

English (EN) (94.79 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 26/11/2014

[View](/en/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-250)

български (BG) (122.17 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/bg/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_bg.pdf)

español (ES) (95.21 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/es/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_es.pdf)

čeština (CS) (120.12 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/cs/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_cs.pdf)

dansk (DA) (94.63 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/da/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_da.pdf)

Deutsch (DE) (96.91 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/de/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_de.pdf)

eesti keel (ET) (94.02 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/et/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_et.pdf)

ελληνικά (EL) (122.56 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/el/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_el.pdf)

français (FR) (96.22 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/fr/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_fr.pdf)

hrvatski (HR) (109.97 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/hr/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_hr.pdf)

italiano (IT) (94.5 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/it/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_it.pdf)

latviešu valoda (LV) (115.94 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/lv/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (116.54 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/lt/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_lt.pdf)

magyar (HU) (115.24 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/hu/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_hu.pdf)

Malti (MT) (119.77 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/mt/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_mt.pdf)

Nederlands (NL) (96.02 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/nl/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_nl.pdf)

polski (PL) (121.14 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/pl/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_pl.pdf)

português (PT) (94.95 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/pt/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_pt.pdf)

română (RO) (117.05 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/ro/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_ro.pdf)

slovenčina (SK) (140.33 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/sk/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_sk.pdf)

slovenščina (SL) (109.71 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/sl/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_sl.pdf)

Suomi (FI) (94.43 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/fi/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_fi.pdf)

svenska (SV) (116.44 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

26/11/2014

[View](/sv/documents/overview/clopidogrel-bgr-previously-zylagren-epar-summary-public_sv.pdf)

## Product information

Clopidogrel BGR : EPAR - Product Information

English (EN) (225.9 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 11/03/2020

[View](/en/documents/product-information/clopidogrel-bgr-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-721)

български (BG) (266.37 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/bg/documents/product-information/clopidogrel-bgr-epar-product-information_bg.pdf)

español (ES) (237.23 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/es/documents/product-information/clopidogrel-bgr-epar-product-information_es.pdf)

čeština (CS) (237.79 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/cs/documents/product-information/clopidogrel-bgr-epar-product-information_cs.pdf)

dansk (DA) (237.49 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/da/documents/product-information/clopidogrel-bgr-epar-product-information_da.pdf)

Deutsch (DE) (246.73 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/de/documents/product-information/clopidogrel-bgr-epar-product-information_de.pdf)

eesti keel (ET) (226.47 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/et/documents/product-information/clopidogrel-bgr-epar-product-information_et.pdf)

ελληνικά (EL) (273.96 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/el/documents/product-information/clopidogrel-bgr-epar-product-information_el.pdf)

français (FR) (244 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/fr/documents/product-information/clopidogrel-bgr-epar-product-information_fr.pdf)

hrvatski (HR) (236.97 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/hr/documents/product-information/clopidogrel-bgr-epar-product-information_hr.pdf)

íslenska (IS) (239.91 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/is/documents/product-information/clopidogrel-bgr-epar-product-information_is.pdf)

italiano (IT) (237.4 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/it/documents/product-information/clopidogrel-bgr-epar-product-information_it.pdf)

latviešu valoda (LV) (231.37 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/lv/documents/product-information/clopidogrel-bgr-epar-product-information_lv.pdf)

lietuvių kalba (LT) (234.45 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/lt/documents/product-information/clopidogrel-bgr-epar-product-information_lt.pdf)

magyar (HU) (255.63 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/hu/documents/product-information/clopidogrel-bgr-epar-product-information_hu.pdf)

Malti (MT) (298.6 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/mt/documents/product-information/clopidogrel-bgr-epar-product-information_mt.pdf)

Nederlands (NL) (263.56 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/nl/documents/product-information/clopidogrel-bgr-epar-product-information_nl.pdf)

norsk (NO) (231.45 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/no/documents/product-information/clopidogrel-bgr-epar-product-information_no.pdf)

polski (PL) (263.68 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/pl/documents/product-information/clopidogrel-bgr-epar-product-information_pl.pdf)

português (PT) (244.81 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/pt/documents/product-information/clopidogrel-bgr-epar-product-information_pt.pdf)

română (RO) (241.91 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/ro/documents/product-information/clopidogrel-bgr-epar-product-information_ro.pdf)

slovenčina (SK) (243.34 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/sk/documents/product-information/clopidogrel-bgr-epar-product-information_sk.pdf)

slovenščina (SL) (232.71 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/sl/documents/product-information/clopidogrel-bgr-epar-product-information_sl.pdf)

Suomi (FI) (236.23 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/fi/documents/product-information/clopidogrel-bgr-epar-product-information_fi.pdf)

svenska (SV) (225.41 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/03/2020

[View](/sv/documents/product-information/clopidogrel-bgr-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0040 24/02/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Clopidogrel BGR (previously Zylagren) : EPAR - All Authorised presentations

English (EN) (19.46 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 11/07/2016

[View](/en/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-812)

български (BG) (42.93 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/bg/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.21 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/es/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.49 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/cs/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.5 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/da/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.56 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/de/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (21.36 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/et/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.46 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/el/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_el.pdf)

français (FR) (19.75 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/fr/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.72 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/hr/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (15.61 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/is/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.47 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/it/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.95 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/lv/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.83 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/lt/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/hu/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.65 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/mt/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.43 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/nl/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.42 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/no/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.17 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/pl/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.52 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/pt/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_pt.pdf)

română (RO) (36.84 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/ro/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.95 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/sk/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.91 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/sl/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.77 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/fi/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.68 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

11/07/2016

[View](/sv/documents/all-authorised-presentations/clopidogrel-bgr-previously-zylagren-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Clopidogrel BGR (previously Zylagren) Active substance clopidogrel (as hydrogen sulfate) International non-proprietary name (INN) or common name clopidogrel Therapeutic area (MeSH)

- Peripheral Vascular Diseases
- Stroke
- Myocardial Infarction

Anatomical therapeutic chemical (ATC) code B01AC03

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Prevention of atherothrombotic events Clopidogrel is indicated in:

Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

## Authorisation details

EMA product number EMEA/H/C/001138

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Biogaran

15, boulevard Charles de Gaulle

Marketing authorisation issued 21/09/2009 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Clopidogrel BGR (previously Zylagren) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (218.46 KB - PDF)

**First published:** 07/09/2010

**Last updated:** 11/03/2020

[View](/en/documents/procedural-steps-after/clopidogrel-bgr-previously-zylagren-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Clopidogrel BGR (previously Zylagren) : EPAR - Public assessment report

English (EN) (244.84 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 14/10/2009

[View](/en/documents/assessment-report/clopidogrel-bgr-previously-zylagren-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use  summary of positive opinion  for Zylagren

English (EN) (78.06 KB - PDF)

**First published:** 24/06/2009

**Last updated:** 24/06/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zylagren_en.pdf)

#### More information on Clopidogrel BGR

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/03/2020

## Share this page

[Back to top](#main-content)